行情

CELG-RT

CELG-RT

Bristol-Myers Squibb Company Celegne Contingent Value Rights
NYSE

实时行情|Nasdaq Last Sale

0.1085
0.00
0.00%
交易中 09:30 05/27 EDT
开盘
--
昨收
0.1085
最高
--
最低
--
成交量
0
成交额
--
52周最高
0.3895
52周最低
0.0373
市值
7,718.69万
市盈率(TTM)
0.0135
分时
5日
1月
3月
1年
5年
暂无数据
暂无数据
了解CELG-RT最新的财务预测,通过CELG-RT每股收益,每股净资产,每股现金流等数据分析Bristol-Myers Squibb Company Celegne Contingent Value Rights近期的经营情况,然后做出明智的投资选择。
暂无数据
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
+0.04%
制药与医学研究
+0.37%
高管信息
Chairman/Chief Executive Officer/Director
Mark Alles
Executive Vice President
Peter Kellogg
Corporate Executive
Terrie Curran
Corporate Executive
Rupert Vessey
Corporate Executive
Michael Pehl
Executive Vice President/General Counsel
Jonathan Biller
Chief Financial Officer/Executive Vice President
David Elkins
Executive Vice President/General Counsel/Secretary
Gerald Masoudi
Lead Director
Michael Casey
Director
Hans Bishop
Director
Julia Haller
Independent Director
Richard Barker
Independent Director
Michael Bonney
Director
Patricia Hall
暂无数据
暂无数据
CELG-RT 简况
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

微牛提供Celgene Corporation(NYSE-CELG RT)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CELG RT股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CELG-RT股票基本功能。